Id: acc4841
Group: 1sens
Protein: alpha-synuclein
Gene Symbol: SNCA
Protein Id: P37840
Protein Name: SYUA_HUMAN
PTM: phosphorylation
Site: Ser129
Site Sequence: PDNEAYEMPSEEGYQDYEPEA
Disease Category: Nervous system diseases
Disease: Parkinson's Disease
Disease Subtype: LRRK2 G2019S?mutation mDAN
Disease Cellline:
Disease Info:
Drug: MLi-2
Drug Info: "MLi-2 is a certain type of drug, whose specific properties and uses may depend on the relevant medical research and practical applications."
Effect: modulate
Effect Info: "Treatment with PFE - 360 and MLi - 2 can reduce the phosphorylation and aggregation of aSyn by inhibiting LRRK2 kinase activity, potentially alleviating the progression of PD."
Note:
Score: 4.0
Pubmed(PMID): 36179692
Sentence Index:
Sentence:

Sequence & Structure:

MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
SNCA CINPANEMAB Alpha-synuclein inhibitor 2 Terminated Parkinson disease ClinicalTrials
SNCA PRASINEZUMAB Alpha-synuclein binding agent 2 Active, not recruiting Parkinson disease ClinicalTrials
ClinicalTrials
SNCA CINPANEMAB Alpha-synuclein inhibitor 1 Completed Parkinson disease ClinicalTrials
SNCA CINPANEMAB Alpha-synuclein inhibitor 1 Terminated Parkinson disease ClinicalTrials
SNCA PRASINEZUMAB Alpha-synuclein binding agent 1 Completed Parkinson disease ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

SNCA-Tyr39
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
SNCAIP-Ser269
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.707
SNCAIP-Ser286
Cancer Intensity
BRCA 1.033
COAD
HGSC
ccRCC
GBM
HNSC -0.069
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.964
SNCAIP-Ser607
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
SNCAIP-Ser609
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC -0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
SNCAIP-Ser610
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
SNCAIP-Ser612
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
SNCAIP-Ser613
Cancer Intensity
BRCA -0.257
COAD
HGSC
ccRCC
GBM 1.103
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.846

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: